| 5.43 -0.08 (-1.45%) | 07-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.08  |
1-year : | 7.56 |
| Resists | First : | 6.06 |
Second : | 6.47 |
| Pivot price | 5.79 |
|||
| Supports | First : | 5.39 |
Second : | 4.48 |
| MAs | MA(5) : | 5.63 |
MA(20) : | 5.87 |
| MA(100) : | 5.43 |
MA(250) : | 4.94 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 15.5 |
D(3) : | 23.5 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 7 | Low : | 2.43 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SVRA ] has closed above bottom band by 19.5%. Bollinger Bands are 29.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.68 - 5.71 | 5.71 - 5.74 |
| Low: | 5.35 - 5.39 | 5.39 - 5.42 |
| Close: | 5.37 - 5.44 | 5.44 - 5.48 |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Tue, 28 Jul 2026
SVRA|Savara Inc|Price:5.435|Chg%:-0.075 - TradingKey
Mon, 27 Jul 2026
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sun, 26 Jul 2026
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA - TradingView
Fri, 24 Jul 2026
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs - Stock Titan
Wed, 22 Jul 2026
Here's Why You Should Add Savara Stock to Your Portfolio Now - Yahoo Finance
Fri, 26 Jun 2026
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 205 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 104.3 (%) |
| Shares Short | 34,140 (K) |
| Shares Short P.Month | 31,360 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -80 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -107 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -9.7 |
| PEG Ratio | 0 |
| Price to Book value | 7.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|